Habtewold, A., Makonnen, E., Amogne, W., Yimer, G., Aderaye, G., Bertilsson, L., . . . Aklillu, E. (2015). Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa?: The HIV-TB pharmagene study. Pharmacogenomics, 16(10), . https://doi.org/10.2217/pgs.15.35
Chicago Style (17th ed.) CitationHabtewold, Abiy, Eyasu Makonnen, Wondwossen Amogne, Getnet Yimer, Getachew Aderaye, Leif Bertilsson, Jürgen Burhenne, and Eleni Aklillu. "Is There a Need to Increase the Dose of Efavirenz During Concomitant Rifampicin-based Antituberculosis Therapy in Sub-Saharan Africa?: The HIV-TB Pharmagene Study." Pharmacogenomics 16, no. 10 (2015). https://doi.org/10.2217/pgs.15.35.
MLA (9th ed.) CitationHabtewold, Abiy, et al. "Is There a Need to Increase the Dose of Efavirenz During Concomitant Rifampicin-based Antituberculosis Therapy in Sub-Saharan Africa?: The HIV-TB Pharmagene Study." Pharmacogenomics, vol. 16, no. 10, 2015, https://doi.org/10.2217/pgs.15.35.